Cybin (CYBN) Price & Analysis

Compare

555 Followers

CYBN Stock Chart & Stats

C$0.14

-C$0.50(-3.50%)

At close: Jan 08 4:00 PM EST

C$0.14

-C$0.50(-3.50%)

Day’s Range― - ―

52-Week RangeC$0.14 - C$0.14

Previous CloseN/A

Volume13.54K

Average Volume (3M)0.00

Market Cap

$1.92M

Enterprise ValueN/A

Total Cash (Recent Filing)$136.29M

Total Debt (Recent Filing)$0.00

Price to Earnings (P/E)―

BetaN/A

Next Earnings

Feb 17, 2026

EPS Estimate

-1.06

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-1.95

Shares Outstanding49,894,130

10 Day Avg. Volume0

30 Day Avg. Volume0

Financial Highlights & Ratios

PEG Ratio>-0.01

Price to Book (P/B)0.62

Price to Sales (P/S)0.00

P/FCF Ratio-2.60

Enterprise Value/Market Cap0.00

Enterprise Value/RevenueN/A

Enterprise Value/Gross Profit0.00

Enterprise Value/Ebitda0.00

Forecast

1Y Price Target

$62.40

Price Target Upside44470.84% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering5

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Clinical Trial ResultsCYB003, in major depressive disorder, showed durable Phase 2 efficacy with an average 23-point reduction in Montgomery–Åsberg Depression Rating Scale scores and 71% remission at 12 months after two 16 mg doses.

Financial StabilityThe recent capital raise provides CYBN with a cash runway into 2027, allowing the company to focus on its strategic goals.

Pipeline DevelopmentCYB004 approaching a key inflection point, with completed enrollment in the Phase 2a trial in generalized anxiety disorder positioning the upcoming readout as a catalyst that could reshape investor perception of DMT programs.

Bears Say

Increased Share CountThe increased share count from the recent financing, normalization of expenses in the model, and fine-tuning the expected CYB003 and CYB004 launches resulted in a revised $55 price target from $150.

Price Target ReductionThe updated model includes a reduced price target from $70 to $45, mainly due to dilution from the recent capital raise.

Cybin News

Psychedelic: Clearmind reports results from first cohort in AUD trial

In this week’s “Psychedelic,” The Fly’s recurring series focused on psychedelic stock news, The Fly looks back on...

5d ago

PBM

CMND

Cybin price target lowered to $45 from $70 at Canaccord

Canaccord lowered the firm’s price target on Cybin (CYBN) to $45 from $70 and keeps a Buy rating...

5d ago

CYBN

Cybin price target lowered to $55 from $150 at H.C. Wainwright

H.C. Wainwright lowered the firm’s price target on Cybin (CYBN) to $55 from $150 and keeps a Buy...

11d ago

CYBN

Psychedelic: Atai Beckley, Cybin report quarterly earnings

In this week’s “Psychedelic,” The Fly’s recurring series focused on psychedelic stock news, The Fly looks back on...

12d ago

PBM

ABBV

Cybin reports Q2 EPS ($1.39), consensus ($1.33)

“We are extremely pleased with the strong demand for our recently completed financing,” said Eric So, Interim CEO....

12d ago

CYBN

Cybin Inc.: Strategic Positioning and Financial Strength Bolster Buy Rating

Cybin, the Healthcare sector company, was revisited by a Wall Street analyst on November 17. Analyst David Martin...

7d ago

CYBN

Cybin, Inc. Reports Q2 2026 Financial Results

Cybin, Inc. ( ($CYBN) ) has released its Q2 earnings. Here is a breakdown of the information Cybin,...

12d ago

CYBN

Cybin, Inc. Navigates Progress and Challenges in Earnings Call

Cybin, Inc. (($TSE:CYBN)) has held its Q2 earnings call. Read on for the main highlights of the call....

12d ago

CYBN

Cybin Inc. Advances Clinical Trials with Strong Financial Backing

Cybin ( ($TSE:CYBN) ) has provided an update. Cybin Inc. reported its financial results for the second quarter...

12d ago

CYBN

Cybin to Present at Jefferies Global Healthcare Conference

Cybin ( ($TSE:CYBN) ) has shared an announcement. Cybin announced that its Chief Business Officer, George Tziras, will...

13d ago

CYBN

Cybin to Release Q2 Financial Results and Business Update

An update from Cybin ( ($TSE:CYBN) ) is now available. Cybin Inc. announced it will release its second...

19d ago

CYBN

Cybin to Engage in Healthcare Innovation Conference

Cybin ( ($TSE:CYBN) ) has shared an announcement. Cybin announced its participation in the Guggenheim 2nd Annual Healthcare...

20d ago

CYBN

Cybin’s CMO to Join Panel at 2025 Milken Institute Health Summit

Cybin ( ($TSE:CYBN) ) has shared an announcement. Cybin announced that its Chief Medical Officer, Amir Inamdar, will...

22d ago

CYBN

Cybin Secures $175 Million in Direct Offering to Boost Mental Health Initiatives

Cybin ( ($TSE:CYBN) ) has provided an update. Cybin announced the closing of a $175 million registered direct...

25d ago

CYBN

CYBN FAQ

What was Cybin’s price range in the past 12 months?

Cybin lowest stock price was C$0.14 and its highest was C$0.14 in the past 12 months.

What is Cybin’s market cap?

Cybin’s market cap is $1.92M.

When is Cybin’s upcoming earnings report date?

Cybin’s upcoming earnings report date is Feb 17, 2026 which is in 84 days.

How were Cybin’s earnings last quarter?

Cybin released its earnings results on Nov 13, 2025. The company reported -C$1.947 earnings per share for the quarter, missing the consensus estimate of -C$1.455 by -C$0.492.

Is Cybin overvalued?

According to Wall Street analysts Cybin’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Cybin pay dividends?

Cybin does not currently pay dividends.

What is Cybin’s EPS estimate?

Cybin’s EPS estimate is -1.06.

How many shares outstanding does Cybin have?

Cybin has 49,894,130 shares outstanding.

What happened to Cybin’s price movement after its last earnings report?

Cybin reported an EPS of -C$1.947 in its last earnings report, missing expectations of -C$1.455. Following the earnings report the stock price went same 0%.

Which hedge fund is a major shareholder of Cybin?

Currently, no hedge funds are holding shares in TSE:CYBN

Company Description

Cybin

Cybin (CYBN) is a biotechnology company focused on advancing psychedelic therapeutics for mental health disorders. Operating primarily in the pharmaceutical sector, Cybin is dedicated to the research and development of psychedelic compounds, aiming to improve patient outcomes through novel drug formulations and delivery systems. The company's core services include clinical trials, drug development, and partnerships with research institutions to explore the therapeutic potential of psychedelics.

Cybin (CYBN) Earnings & Revenues

Historic Earnings Reports

CYBN Earnings Call

Q2 2025

0:00 / 0:00

Earnings Call Sentiment|Neutral

The earnings call reflects a company making significant progress in advancing its clinical programs and strengthening its financial position, despite facing challenges such as leadership transition and increased expenses. The overall sentiment is balanced, with solid achievements in clinical and operational fronts but offset by financial and leadership concerns.View all TSE:CYBN earnings summaries

CYBN Stock 12 Month Forecast

Average Price Target

C$62.40

▲(44470.84% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"78":"C$78","-1":"-C$1","18.75":"C$18.75","38.5":"C$38.5","58.25":"C$58.3"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":77.55829565,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">C$77.56</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":62.3991742275,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">C$62.40</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":42.3045249,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">C$42.30</span>\n  </div></div>","useHTML":true}}],"tickPositions":[-1,18.75,38.5,58.25,78],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Feb<br/>2025","6":"May<br/>2025","9":"Aug<br/>2025","12":"Nov<br/>2025","25":"Nov<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,0.135,6.090638126923077,12.046276253846154,18.001914380769232,23.95755250769231,29.913190634615386,35.86882876153846,41.82446688846154,47.78010501538461,53.73574314230769,59.69138126923077,65.64701939615385,71.60265752307693,{"y":77.55829565,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,0.135,4.924551863653846,9.714103727307693,14.50365559096154,19.293207454615388,24.082759318269236,28.87231118192308,33.66186304557692,38.45141490923077,43.24096677288462,48.03051863653847,52.82007050019231,57.60962236384616,{"y":62.3991742275,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,0.135,3.3788096076923075,6.622619215384615,9.866428823076923,13.11023843076923,16.35404803846154,19.597857646153848,22.841667253846158,26.085476861538464,29.32928646923077,32.57309607692307,35.816905684615385,39.06071529230769,{"y":42.3045249,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":0.135,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.135,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.135,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.135,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.135,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.135,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.135,"date":1746057600000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":0.135,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.135,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.135,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.135,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.135,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.135,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >